



Program Hebron Congress

10 November 2016

09:30-10:00	Welcome and coffee/tea
10:00-10:55	Session 1 – Tumor testing and prognostic markers
<u>Linn</u>	Genomewide DNA copy number patterns resembling gBRCAm tumors: Clinical applications
<u>Fakkert</u>	BRCA testing in Ovarian tumors initiated by a Pathologist (OPA): a pre-screen for germline testing and therapy choice
<u>Hollestelle</u>	High nuclear FTH1 expression predicts early recurrence for BRCA1/2 mutation carriers
10:55-11:25	Coffee/tea break
11:25-12:40	Session 2 – Hormonal/lifestyle risk factors of breast cancer among BRCA1/2 mutation carriers - first prospective results IBCCS/kConFab/BCFR
<u>Antoniou</u>	Absolute risks of breast cancer, contralateral breast cancer and ovarian cancer
<u>Mavaddat</u>	Age at menarche, age at menopause and risk reducing oophorectomy
<u>Andrieu</u>	Reproductive risk factors
12:40-13:40	Lunch break
13:40-14:30	Session 3 – Hormonal/lifestyle risk factors of breast cancer among BRCA1/2 mutation carriers - first prospective results IBCCS/kConFab/BCFR (continued)
<u>Schrijver</u>	Oral contraceptives
<u>Goldgar</u>	Alcohol and smoking
14:30-15:20	Session 4 – Related ongoing studies
<u>van 't Veer</u>	Athena Wisdom
<u>Simard</u>	Perspectives (B-Cast/ BRIDGES talk)
15:20-15:50	Coffee/tea break
15:50-16:15	Session 5 – Risk prediction
<u>Easton</u>	The polygenetic risk score; new genetic findings in BRCA and non-BRCA families
16:15-17:00	Session 6 – Risk factors for (contralateral) breast cancer and ovarium cancer
<u>Hooning</u>	Risk factors for metachronous contralateral breast cancer: systematic review and meta-analysis
<u>van den Broek</u>	BRCA1 mutation location and risk of subsequent contralateral breast or ovarian cancer after breast cancer
<u>Heemskerk-Gerritsen</u>	Risk of primary and contralateral breast cancer in BRCA1/2 mutation carriers with a history of ovarian cancer
17:00	Drinks